In this commentary, Sandra P. D’Angelo, MD, highlights the practice-changing use of immune checkpoint inhibitor therapy for the treatment of patients with metastatic Merkel cell carcinoma.
In this commentary Shailender Bhatia, MD, shares his perspective on the unprecedented efficacy of immunotherapy in treating a patient with bulky metastatic MCC.
In this commentary, Howard L. Kaufman, MD, highlights practice-changing clinical trial results on avelumab, the first FDA-approved treatment for metastatic Merkel cell carcinoma.
With avelumab now approved for MCC, what treatment options are available to patients not responding to checkpoint inhibitors? Read my thoughts on a promising new approach.